Skip to main content
SpringerLink
Log in

Solifenacin in Overactive Bladder Syndrome

  • Adis Drug Profile
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

▴ Solifenacin is a bladder-selective, muscarinic (M1 and M3) receptor antagonist. In animal studies, the selectivity of solifenacin for the bladder over the salivary glands was greater than that of tolterodine, oxybutynin, darifenacin or atropine.

▴ In large, 12-week, randomised, double-blind, multicentre clinical trials, solifenacin 5 and 10mg once daily improved symptoms of overactive bladder syndrome (OAB) [urinary urgency, frequency, incontinence and nocturia] and increased functional bladder capacity to a significantly greater extent than placebo.

▴ Solifenacin 5 or 10mg once daily was noninferior to tolterodine extended release (ER) 4mg daily for improving urinary frequency and had significantly greater efficacy than tolterodine ER for improving other symptoms of OAB (episodes of urgency, incontinence and urge incontinence) and increasing functional bladder capacity.

▴ At least half of all patients receiving solifenacin who were incontinent at baseline were continent by study end in the three comparative studies reporting this parameter.

▴ Health-related quality of life was significantly improved with once-daily solifenacin 5 or 10mg versus placebo, as assessed in two 12-week double-blind studies; the improvement was maintained during a 40-week extension study.

▴ Solifenacin was generally well tolerated; the most frequently reported adverse events were dry mouth, constipation and blurred vision.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurology 2004; 3(1): 46–53

    Article  PubMed  CAS  Google Scholar 

  2. Herbison P, Hay-Smith J, Ellis G, et al. Effectiveness of cholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003; 326: 841–4

    Article  PubMed  CAS  Google Scholar 

  3. Nitti VW. Clinical impact of overactive bladder. Reviews in Urology 2002; 4(Suppl. 4): S2–6

    PubMed  Google Scholar 

  4. Debruyne FMJ, Heesakkers JPFA. Clinical and socioeconomic relevance of overactive bladder. Urology 2004; 63 (3 Suppl. 1): 42–4

    Article  PubMed  Google Scholar 

  5. Abrams P, Kelleher CJ, Kerr LA, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000 Jul; 6 (11 Suppl.): S580–90

    PubMed  CAS  Google Scholar 

  6. Wein AJ. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Expert Opin Investig Drugs 2001 Jan; 10(1): 65–83

    Article  PubMed  CAS  Google Scholar 

  7. Chapple CR, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology 2002 Nov; 60 (5 Suppl. 1): 82–8; discussion 88–9

    Article  PubMed  Google Scholar 

  8. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000 May; 55(5A Suppl.): 33–46; discussion 50

    Article  PubMed  CAS  Google Scholar 

  9. Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005 Mar; 47(3): 376–84

    Article  PubMed  CAS  Google Scholar 

  10. Ikeda K, Kobayashi S, Suzuki M, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn-Schmiedebergs Arch Pharmacol 2002 Aug; 366(2): 97–103

    Article  PubMed  CAS  Google Scholar 

  11. Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004 May 25; 492(2–3): 243–50

    Article  PubMed  CAS  Google Scholar 

  12. Kobayashi S, Ikeda K, Miyata K. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci 2004 Jan 2; 74(7): 843–53

    Article  PubMed  CAS  Google Scholar 

  13. Robinson D, Cardozo L. The emerging role of solifenacin in the treatment of overactive bladder. Expert Opin Investig Drugs 2004 Oct; 13(10): 1339–48

    Article  PubMed  CAS  Google Scholar 

  14. Smulders RA, van Alphen W, Visser J, et al. Multiple dosing with YM905, a novel, bladder-selective antimuscarinic, in healthy men: safety and tolerability and pharmacokinetics. 32nd Annual Meeting of the International Incontinence Society; 2002 Aug 27–30; Heidelberg

  15. Kuipers ME, Krauwinkel WJJ, Mulder H, et al. Solifenacin demonstrates high absolute bioavailability in healthy men. Drugs RD 2004; 5(2): 73–81

    Article  CAS  Google Scholar 

  16. Uchida T, Krauwinkel WJ, Mulder H, et al. Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial. Br J Clin Pharmacol 2004 Jul; 58(1): 4–7

    Article  PubMed  CAS  Google Scholar 

  17. Krauwinkel WJ, Smulders RA, Mulder H, et al. Effect of age on the pharmacokinetics of solifenacin in men and women. Int J Clin Pharmacol Ther 2005 May; 43(5): 227–38

    PubMed  CAS  Google Scholar 

  18. Smith N, van Zijtveld J, Swart PJ, et al. Co-administration of ketoconazole, a potent CYP3A4 inhibitor, does not affect safety or tolerability of YM 905. 32nd Annual Meeting of the International Incontinence Society; 2002 Aug 27–30; Heidelberg

  19. VESIcare® (solifenacin succinate) prescribing information. Paramus (NJ): Yamnouchi Pharma America, Inc. and Research Triangle Park (NC): GlaxoSmithKline, 2004

  20. Chapple CR, Martinez-Garcia, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome; results of the STAR trial. Eur Urol 2005; 48(3): 464–70

    Article  PubMed  CAS  Google Scholar 

  21. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004 Feb; 93(3): 303–10

    Article  PubMed  CAS  Google Scholar 

  22. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily muscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: 1919–24

    Article  PubMed  CAS  Google Scholar 

  23. Gittelman M, Chu FM, Klimberg I, et al. Two randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter studies assess the efficacy and safety of daily oral administration of 10 mg YM905 versus placebo in male and female subjects with overactive bladder. J Urol 2003 Apr; 169 (Suppl.): 349

    Google Scholar 

  24. Kelleher CJ, Cardozo L, Chapple CR, et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005 Jan; 95(1): 81–5

    Article  PubMed  Google Scholar 

  25. Lucente V, Swift S. Urgency episodes were statistically reduced with solifenacin treatment for overactive bladder. 2004 Joint Scientific Meeting. The American Urogynecologic Society and The Society of Gynecologic Surgeons; 2004 July 29–31; San Diego, CA

  26. Garely AD. Solifenacin succinate once daily is superior to placebo in all major overactive bladder symptoms in four trials: results in women. Obstet Gynecol 2004 Apr; 103(Suppl. 4): 129

    Google Scholar 

  27. Kaufman J, Knapp P, Siami P, et al. YM905 10 mg increases the proportion of male and female patients with overactive bladder who become continent. J Am Geriatr Soc 2003 Apr; 51 (Suppl.): 100

    Google Scholar 

  28. Chapple CR, Arano P, Bosch JLHR, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004 Jan; 93(1): 71–7

    Article  PubMed  CAS  Google Scholar 

  29. Yamnouchi Pharma Ltd. Vesicare® 5mg and 10mg film-coated tablets. Special Product Characteristics [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2004 Nov 26]

Download references

Acknowledgements

At the request of the journal, Astellas Pharma Inc. provided a non-binding review of this article.

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand, New Zealand

    Dene Simpson & Antona J. Wagstaff

Authors
  1. Dene Simpson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antona J. Wagstaff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dene Simpson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simpson, D., Wagstaff, A.J. Solifenacin in Overactive Bladder Syndrome. Drugs Aging 22, 1061–1069 (2005). https://doi.org/10.2165/00002512-200522120-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200522120-00005

Keywords

Search

Navigation